Back to top
more

Genmab (GMAB)

(Delayed Data from NSDQ)

$29.72 USD

29.72
721,131

+2.00 (7.22%)

Updated May 3, 2024 04:00 PM ET

After-Market: $29.73 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Elevance Health (ELV) and Genmab AS Sponsored ADR (GMAB) have performed compared to their sector so far this year.

AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag

by Zacks Equity Research

The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL.

Humana's (HUM) Arm to Aid Senior Care, 2023 Expansion on Track

by Zacks Equity Research

Humana's (HUM) CenterWell brand plans to open centers in untapped markets as well as dig deeper into the existing regions offering enhanced primary care services to the nation's senior citizens.

Can Genmab AS Sponsored ADR (GMAB) Run Higher on Rising Earnings Estimates?

by Zacks Equity Research

Genmab AS Sponsored ADR (GMAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Genmab AS Sponsored ADR (GMAB) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PBYI vs. GMAB: Which Stock Is the Better Value Option?

Is Genmab (GMAB) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Genmab AS Sponsored ADR (GMAB) and Nuvalent, Inc. (NUVL) have performed compared to their sector so far this year.

Is a Surprise Coming for Genmab (GMAB) This Earnings Season?

by Zacks Equity Research

Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Sundeep Ganoria headshot

4 Biotech Stocks Set to Outpace Q3 Earnings Estimates

by Sundeep Ganoria

Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.

Centene (CNC) to Post Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Centene's (CNC) third-quarter results are likely to reflect higher premiums and contract wins enjoyed by its Medicaid business, partly offset by escalating operating expenses.

INCY vs. GMAB: Which Stock Is the Better Value Option?

by Zacks Equity Research

INCY vs. GMAB: Which Stock Is the Better Value Option?

Will UnitedHealth Group (UNH) Beat Q3 Earnings Estimates?

by Zacks Equity Research

UnitedHealth Group's (UNH) third-quarter results are likely to benefit from higher premiums and membership growth in its UnitedHealthcare unit, partly offset by elevated technology investment costs.

Should You Buy Genmab (GMAB) Ahead of Earnings?

by Zacks Equity Research

Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Genmab (GMAB), AbbVie's Epcoritamab Successful in LBCL Study

by Zacks Equity Research

Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for hematologic malignancies including NHL and LBCL. A phase I/II study evaluating it in LBCL achieves a response rate of 63%.

Seagen (SGEN) Inks ADC Deal With Sanofi for Cancer Targets

by Zacks Equity Research

Seagen (SGEN) inks a collaboration agreement with Sanofi to develop and commercialize antibody-drug conjugates for three cancer targets.

Genmab (GMAB), AbbVie Lymphoma Candidate Gets Orphan Drug Tag

by Zacks Equity Research

Genmab (GMAB) and AbbVie are co-developing epcoritamab as a potential treatment for non-Hodgkin's lymphoma, follicular lymphoma. The FDA grants orphan drug status for the candidate as a treatment for FL.

Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry

by Zacks Equity Research

Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.

Seagen (SGEN) Completes Enrollment in Colorectal Cancer Study

by Zacks Equity Research

Seagen (SGEN) enrolls the last patient in the phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin, and as a single agent for treating HER2-positive metastatic colorectal cancer.

Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer (Revised)

by Zacks Equity Research

The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.

Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer

by Zacks Equity Research

The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.

    AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy

    by Zacks Equity Research

    AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.

    Is a Surprise Coming for Genmab (GMAB) This Earnings Season?

    by Zacks Equity Research

    Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

    Seagen (SGEN) Q2 Earnings Beat Estimates, Revenues Surge Y/Y

    by Zacks Equity Research

    Seagen (SGEN) reports narrower-than-expected loss for the second quarter of 2021 while revenues beat estimates.

    ALXN or GMAB: Which Is the Better Value Stock Right Now?

    by Zacks Equity Research

    ALXN vs. GMAB: Which Stock Is the Better Value Option?

    Seagen (SGEN) Q1 Loss Wider Than Expected, Revenues Rise Y/Y

    by Zacks Equity Research

    Seagen (SGEN) lags estimates for earnings and revenues in the first quarter of 2021. Shares lose ground in after-hour trading.